Because in the $40/$41 range all that bad news is in the price, you get paid 3.5% dividend, you keep writing options for about two years in the $47/$50 area collecting probably another 10% to 15% in the process, and you are buying MRK at an historical low PE of 14 (all that around the $40/$41 zone). You are buying one of the five best sales and marketing outfits in the Pharma sector, all that while waiting through the next bear in the high flyers. I would not write them off, yet.